Search results
Results From The WOW.Com Content Network
HIV Drug Resistance Database, also known as Stanford HIV RT and Protease Sequence Database, is a database at Stanford University that tracks 93 common mutations of HIV. It has been recompiled in 2008 listing 93 common mutations, after its initial mutation compilation in 2007 of 80 mutations. The latest list utilizes data from other laboratories ...
The Stanford HIV RT and Protease Sequence Database (also called the “HIV Drug Resistance Database”) was formed in 1998 with HIV reverse transcriptase and protease sequences from persons with well-characterized antiretroviral treatment histories, and is publicly available to query resistance mutations and genotype-treatment, genotype ...
The Stanford HIV Drug Resistance Database and the International AIDS Society publish lists of the most important of these; first year listing 80 common mutations, and the latest year 93 common mutations, and made available through the Stanford HIV RT and Protease Sequence Database. [citation needed]
Innate resistance to HIV. A small proportion of humans show partial or apparently complete innate resistance to HIV, the virus that causes AIDS. [1] The main mechanism is a mutation of the gene encoding CCR5, which acts as a co-receptor for HIV. It is estimated that the proportion of people with some form of resistance to HIV is under 10%.
Resistance Database Initiative. HIV Resistance Response Database Initiative ( RDI) was formed in 2002 to use artificial intelligence (AI) to predict how patients will respond to HIV drugs using data from more 250,000 patients from around 50 countries around the world. The RDI used its models to power its HIV Treatment Response Prediction System ...
As of July 2017, the WHO is implementing the Global Action Plan on HIV drug resistance 2017–2021. It is a 5-year initiative intended to help countries around the world manage HIV drug resistance. [19] Among treatment methods, the World Health Organization acknowledges the importance of successful first-line treatments. [18]
The genome and proteins of HIV (human immunodeficiency virus) have been the subject of extensive research since the discovery of the virus in 1983. [1] [2] "In the search for the causative agent, it was initially believed that the virus was a form of the Human T-cell leukemia virus (HTLV), which was known at the time to affect the human immune system and cause certain leukemias.
Management of HIV/AIDS. The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [ 1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active ...